Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - SHARE PURCHASE PURSUANT TO RESTRICTED SHARE AWARD SCHEME2023.12.05
-
VOLUNTARY ANNOUNCEMENT - FIRST DOSE OF THE FIRST BATCH OF SUBJECTS IN PHASE I CLINICAL TRIAL OF TQA3038 "siRNA" COMPLETED2023.12.05
-
VOLUNTARY ANNUONCEMENT - SINO BIOPHARMACEUTICAL AWARDED "2023 FORBES CHINA ESG INNOVATIVE ENTERPRISE"2023.12.04
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 20232023.12.01
-
VOLUNTARY ANNOUNCEMENT - APPROVAL OF CLINICAL TRIAL FOR TQB3015 "ATR KINASE INHIBITOR" TABLET2023.11.28
-
VOLUNTARY ANNOUNCEMENT - DISPOSAL OF EQUITY INTERESTS IN THREE SUBSIDIARIES2023.11.08
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 20232023.11.01
-
VOLUNTARY ANNOUNCEMENT - SINO BIOPHARMACEUTICAL MSCI ESG RATING UPGRADED TO "A"2023.11.01